Tubacex Swings to 9M 2026 Net Loss of €5.5 Million
Bitget2026/10/30 07:37- Tubacex swung to an attributable net loss of €5.5 million in the first nine months of 2026.
- Sales fell 10% year over year to €475.6 million, reflecting lower order intake during 2025.
- EBITDA dropped 36% year over year to €54 million, hurt by lower activity and higher logistics and energy costs.
- Net financial debt reached €405 million at September-end, with the increase directly linked to the ADNOC supply chain.
- The order book rose from June to €1.16 billion at September-end, marking the first stabilization after several quarters of decline.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
